Yahoo
    Shenzhen - Delayed Quote CNY

    Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)

    54.82 -3.13 (-5.40%)
    At close: October 30 at 3:04:45 PM GMT+8
    Loading Chart for 002653.SZ
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

    AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group
    GlobeNewswire 1mo ago
    Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners

    Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
    PR Newswire 2mo ago
    Haisco and Nuvectis sign licensing deal for two drugs

    Haisco and Nuvectis sign licensing deal for two drugs
    Pharmaceutical Technology 4mo ago
    Haisco and Nuvectis sign licensing deal for two drugs

    Haisco and Nuvectis sign licensing deal for two drugs
    Hospital Management 4mo ago
    Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas

    Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
    PR Newswire 4mo ago
    Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)

    Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)
    InvestorsHub 4mo ago
    Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

    Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
    Zacks 2mo ago
    StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

    StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
    TMX Newsfile 3mo ago
    Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

    Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
    GlobeNewswire 4mo ago
    AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

    AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
    Insider Monkey 6mo ago
    Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets

    Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets
    Simply Wall St. 4mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: